In this multicenter trial, postmenopausal, ER+ breast cancer patients were randomized to receive either aromatase inhibitor alone (CG) or in combination with tecemotide (VG); premenopausal, TNBC, or ER− subtypes received either anthracycline-and-taxane-based chemotherapy alone (CG) or combined with tecemotide (VG). Here, CYP19A1 is linked to breast carcinoma.